Skip to main content

Table 1 Baseline characteristics of patients

From: Accuracy of the clinical pulmonary infection score to differentiate ventilator-associated tracheobronchitis from ventilator-associated pneumonia

 

Derivation cohort

P value

Validation cohort

P value

VAT (n = 320)

VAP (n = 369)

VAT (n = 70)

VAP (n = 136)

Sex

 Male

199 (62%)

264 (72%)

 

51 (73%)

102 (75%)

 

 Female

121 (38%)

105 (28%)

0.009

19 (27%)

34 (25%)

0.74

Age (years)

61.20 (16.25)

57.74 (18.46)

0.009

55.26 (16.1)

54.98 (16.36)

0.89

SAPS II

48.85 (18.12)

49.89 (17.80)

0.45

54.6 (19.46)

59.97 (16.68)

0.079

SOFA

7.64 (3.79)

8.07 (3.63)

0.13

7.19 (4.34)

8.9 (4.04)

0.008

Admission category

 Medical

175 (55%)

218 (59%)

 

57 (81%)

117 (86%)

 

 Surgical

145 (45%)

151 (41%)

0.25

13 (19%)

19 (14%)

0.39

 COPD

64 (20%)

61 (17%)

0.24

6 (10%)

21 (15%)

0.17

 Diabetes mellitus

66 (21%)

69 (19%)

0.53

14 (20%)

26 (20%)

0.88

 Immunocompromised patients

24 (8%)

31 (8%)

0.66

7 (10%)

23 (17%)

0.18

 Chronic heart failure

27 (8%)

19 (5%)

0.085

16 (23%)

16 (12%)

0.037

 Chronic respiratory failure

35 (11%)

27 (7%)

0.098

3 (4%)

7 (5%)

0.78

 Cirrhosis

8 (2%)

23 (6%)

0.018

3 (4%)

10 (7%)

0.38

 Previous antibiotic use

210 (66%)

232 (63%)

0.45

60 (86%)

107 (79%)

0.3

 Appropriate initial antimicrobial therapy

174 (54%)

257 (70%)

< 0.001

40 (57%)

55 (40%)

0.023

  1. Data are presented as number (%) or mean (SD)
  2. COPD Chronic obstructive pulmonary disease, SAPS Simplified acute physiology score, SOFA Sequential organ failure assessment, VAP Ventilator-associated pneumonia, VAT Ventilator-associated tracheobronchitis
  3. p value < 0.05 is indicated in italic characters